Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393327 | 0.87 | MAPT (0.51) | KDM4ESMN1; SMN2MAPTKMT2AL3MBTL1 | |
| SCHEMBL394359 | 0.79 | HRH3 (0.43) | KDM4ESMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL393653 | 0.77 | ADRB2 (0.46) | KDM4EMAPTKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL394164 | 0.77 | KDM4E (0.43) | KDM4EMAPTKMT2AL3MBTL1MEN1 | |
| SCHEMBL392988 | 0.75 | KDM4E (0.46) | KDM4ESMN1; SMN2MAPTKMT2AL3MBTL1 | |
| SCHEMBL390381 | 0.75 | MAPK1 (0.41) | SMN1; SMN2MAPTKMT2AALDH1A1GAA | |
| SCHEMBL394011 | 0.74 | MEN1 (0.55) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL438867 | 0.74 | KDM4E (0.46) | KDM4ESMN1; SMN2MAPTKMT2AL3MBTL1 | |
| SCHEMBL393416 | 0.74 | ADRB2 (0.44) | MAPTPOLB | |
| SCHEMBL393282 | 0.73 | ADRB2 (0.43) | KDM4ESMN1; SMN2MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919879-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2007027599-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | WYETH (US) | 2007-03-08 | — | — | WO | claimed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | claimed |
| US-8101590-B2 | 9-aminocarbonylsubstituted derivatives of glycylcyclines | WYETH LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1919879-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027599-A1 | 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES | WYETH (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | Q6ZSR9, GMPS, RPS10 | KDM4E 1240/4885SMN1; SMN2 4211/4885MAPT 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.